To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT05948449 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: S-1, Oxaliplatin, Cadonilimab

Sponsor

Sichuan University